The European Medicines Agency has accepted a marketing authorization application for olaparib to treat women with BRCA-mutated, HER2-negative metastatic breast cancer who previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
Original Article: EMA to Review Olaparib in BRCA-mutated, HER2-negative Breast Cancer